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Drug metabolism and pharmacokinetics (DMPK) have
improved success rates of drug discovery and development
in the last two decades1–5. The contributions and improvement
to the success rates by DMPK can be attributed to at least
three reasons. First, DMPK is now routinely incorporated
into early drug discovery, a trend beginning about 15–20 years
ago. Second, DMPK scientists have a better understanding of
drug metabolic enzymes, transporters, and differences among
species and individuals. Many research tools and advanced
instrumentation are now available to make relatively reliable
predictions from the in vitro to the in vivo data and from
animals to humans. Third, strategies for the optimization of
appropriate DMPK properties have been formed, improved
and applied to drug discovery and development.
As shown in Fig. 1, absorption, distribution, metabolism
and excretion (ADME) studies are important for drug dis-
covery and development. In fact, the ADME parameters
obtained from in vitro and in vivo models, which aid in the
prediction of drug behaviors in patients, are important for the
decision to advance, hold or terminate a drug candidate.
However, incomplete ADME studies or misinterpretation of
ADME data may cause failures in drug development. ADME
studies are conducted with in vitro, in vivo or in silico models.
In vitro models generate many ADME parameters, including
apparent permeability, metabolic stability, reaction phenotyp-
ing, protein binding, blood-to-plasma partitioning, drug–drug
interaction potentials (e.g., inhibition and induction ofTypical model systems used in scytochrome P450 (CYP) and transporters), cell proliferation
and cytotoxicity, and hERG inhibition. In vivo models of
animals and healthy human subjects provide information such
as drug oral bioavailability, exposures, distribution, clearance,
and duration of exposure for a drug and its metabolites.
Finally, in silico models predict drug behaviors based on
physicochemical properties of drug candidates in combination
with crystal structures of a protein (an enzyme or a transpor-
ter) and database of ADME properties generated in labora-
tories. Major model systems needed for particular studies are
listed in Table 1. With the numerous models available, proper
experimental model selection is essential for ADME property
optimization.
A few common strategies for ADME property optimiza-
tion, highlighted in this paragraph, will be described in the
following sections, which include step-by-step, issue-driven,
PK–PD and PK–TK considerations. During the early and
middle stages of drug discovery (also called lead identiﬁcation
and optimization), ADME screening is conducted, usually in a
high throughput mode. ADME screening usually includes, but
is not limited to, determinations of human and animal liver
microsomal stability, human CYP inhibition, apparent perme-
ability (using parallel artiﬁcial membrane permeation assays
(PAMPA) and/or Caco-2 cells), PK, metabolic soft spots,
reactive metabolites and activation of pregnane X receptor
(PXR) (using reporter gene assays). In the late stage of drug
discovery (also called clinical candidate characterization),
more comprehensive ADME properties of drug candidates
will be determined. DMPK studies at this stage include, buttaged drug discovery and development.
Table 1 Model systems for particular studies.
ADME study Test system
Metabolic stability Liver preps, enzymes
Metabolite ID Liver preps, bioreactors, in vivo
Reaction phenotyping Microsome, hepatocyte, enzyme
CYP inhibition Microsome, hepatocyte, enzyme
CYP induction Microsome, ex vivo
Transporters Caco-2 and other cell lines
Plasma protein binding Plasma
Mass balance Animals and human subjects
Metabolite proﬁling Animals and human subjects
Disposition Healthy subjects or patients
Species comparison Animals and humans
Tissue distribution Rats
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partitioning and plasma stability), hepatocyte stability, meta-
bolic enzyme phenotyping, human CYP inhibition,
mechanism-based inactivation, ADME studies in animals
(including oral and i.v. PK studies), mass balance, drug
distribution (using quantitative whole body autoradiography)
(QWBA), drug elimination pathways (using bile-duct cannu-
lated animals), ex vivo induction (if needed), metabolite
identiﬁcation (Met ID), transporter substrate and/or inhibitor
evaluation, human CYP induction (using human hepatocytes),
drug–drug interaction evaluation, and DMPK modeling
(which includes scaling up from in vitro to in vivo, and from
preclinical animals to humans, and human dosing projection).
The key transporters that need to be evaluated are efﬂux
transporters, including P-glycoprotein (P-gp) and breast can-
cer resistance protein (BCRP), as well as bile salt export pump
(BSEP) and uptake transporters, including organic anion
transporter (OAT) 1 and 3, organic cation transporter
(OCT) 2, organic anion transporting peptide (OATP) 1B1
and 1B36.2. ADME experimental models
2.1. In vitro metabolic models
In DMPK, ‘‘drug-like’’ properties commonly refer to respect-
able absorption, adequate distribution, low metabolism, com-
plete elimination from body and minimal toxicological risk.
In vitro assays, which play an essential role in screening
chemical entities in the discovery stage, have many unique
advantages. First, these assays provide a simple, convenient
and fast way to test the potency and drug-like properties of
chemical entities. Second, in vitro assays require limited
amounts of test compound, which is appealing since com-
pound supply is limited at the early drug discovery stage and it
is not always feasible to perform preclinical animal studies.
Third, in vitro assays are often designed to answer speciﬁc
questions, such as structure–activity relationship (SAR) for
metabolic stability or DDI potential of the drug candidates;
answers to these questions may be difﬁcult to obtain in animal
studies due to confounding factors. Fourth, human-based
in vitro assays could provide a more accurate estimation of
human clinical outcomes than could animal tests at the
preclinical stage, especially for properties that are known tohave species-related differences (between preclinical animals
and humans) and where strong in vitro–in vivo correlations
have already been established in humans. An example of such
a property is CYP enzyme induction. It has been shown that
preclinical species cannot always predict human CYP induc-
tion potential due to species related differences. However, a
good in vitro–in vivo correlation has been observed in humans.
For instance, a negative induction in human in vitro studies
using primary hepatocyte cultures seemed to always link to a
negative induction observed in humans in clinical studies.
Therefore, FDA typically waives clinical DDI studies if the
drug candidate is tested negative in a human in vitro CYP
induction study.
The prediction of human efﬁcacy and DMPK/toxicology
properties from preclinical studies is perhaps the ultimate goal
of drug discovery. A common practice in pharmaceutical
industry is to establish in vitro–in vivo correlation for an
ADME parameter in multi-species preclinical studies, and
then ﬁnd the species that correlates to humans. If the in vitro–
in vivo correlation is established in an animal species and the
in vitro correlation between the animal species and humans is
also established, then the human in vitro information could be
used to predict the clinical ADME outcome (Fig. 2). On the
other hand, if the in vivo correlation for a parameter between
animal and human is well understood, then animal in vivo data
could be used to predict human outcomes. Examples of
parameters often used for such predictions include human
efﬁcacy, PK properties (e.g., target inhibition, absorption and
clearance) and toxicological endpoints (e.g., QT prolonga-
tion). Once the in vitro–in vivo or animal to human correla-
tions are established, the estimations, for example, of human
clearance from human in vitro clearance data, of human
efﬁcacy from xenograft mouse model, or of human QT
prolongation risk from dog studies, are possible. In general,
DMPK parameters are extrapolated from (1) comparisons of
in vitro data across species and/or (2) in vitro–in vivo correla-
tion in animals. Notably, in vivo models provide combined
effects of permeability, distribution, metabolism and elimina-
tion. Thus, they have limitations for such applications as to
pinpoint a speciﬁc factor in an observation. For example, it
would be hard to rely only on differences in permeability,
without considering differences in ﬁrst-pass metabolism, to
evaluate bioavailability among a series of drug candidates.2.1.1. Expressed enzymes
A primary application of expressed enzymes is to conduct
reaction-phenotyping for drug candidates. The FDA DDI
guidance7 requires conducting clinical DDI trial if a com-
pound has greater than 25% of its clearance mediated by a
particular pathway. CYP metabolism is the most common
clearance pathways for the elimination of drugs. Thus,
identifying the relative contributions of each CYP isoforms
to the total hepatic clearance is an essential task. Additionally,
when the CYP metabolism data are combined with data on
other non-metabolic clearance pathways, such as renal or
biliary clearance, estimations can be made on the contribu-
tions of each CYP isoform to the total body clearance of a
drug. A second application of expressed enzymes is to
qualitatively identify the involvement of CYPs in metabolic
pathways (often referred to as CYP mapping). This assay
provides important information on whether the drug candidate
Figure 2 A model of using in vitro–in vivo correlation in preclinical species, combined with human in vitro studies, to predict human
clinical outcomes.
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furthermore, whether highly polymorphic enzymes, such as
CYP2D6 and CYP2C19, are the major contributors to its
metabolic clearance. It should be noted that, while in most cases
hepatic metabolism are performed by the primary drug-
metabolizing CYPs, other enzymes could also contribute signiﬁ-
cantly to the overall metabolism. Examples of non-CYP micro-
somal or cytosolic enzymes often involved in drug metabolism
include ﬂavin-containing monooxygenases (FMO), UDP-
glucuronosyltransferases (UGT), sulfotransferases (SULT) and
aldehyde oxidases (AO)8,9.
Expressed enzymes are also used for mechanistic applica-
tions. The example described by Li and colleagues10 featured
the use of expressed enzymes, either incubated separately or
else in combination with each other; the results elucidated that
CYP3A4 was involved in the generation of a metabolite that,
in turn, was responsible for time-dependent inhibition (TDI)
of CYP2D6. Additionally, since expressed CYP systems are
concentrated enzymes with high activity toward a speciﬁc
substrate, they are often used as ‘‘bioreactors’’ to generate
metabolites of interest for further testing. Using the generated
metabolites that are collected as chromatographic fractions, it
is possible to test for pharmacological activity without the
need to identify the metabolite structures. In this application,
the high activity and selectivity of expressed enzymes provide a
superior alternative to the use of human liver microsomes
(HLMs), as HLMs tend to generate greater numbers of
metabolites. The potential presence of additional metabolites
adds difﬁculty to liquid chromatographic separation; however,
the added expense of using expressed CYPs provides its own
challenges.2.1.2. Sub-cellular fractions
Along with the expressed enzyme systems, sub-cellular frac-
tions prepared from drug metabolizing tissues (liver and gut),
including cytosol, S9 and microsomal fractions, are used in
drug metabolism studies to address various questions. The
cytosol, which is isolated as a supernatant from the S9
fraction, contains a group of soluble drug-metabolizing
enzymes responsible for speciﬁc routes of drug metabolism.
It is the simplest system of the three. The S9 fraction contains
both cytosol and microsomes, and represents a nearly com-
plete collection of all drug metabolizing enzymes. However,
the presence of so many enzymes can sometimes dilute the
activities of the enzyme of interest. The microsomal fraction
contains membrane-bound CYPs and primary conjugationenzymes such as UGTs. These enzymes are responsible for the
metabolism of over 90% of marketed drugs, thus this is the
most frequently utilized enzyme system.
The cytosol is often used to conduct mechanistic studies for
identifying the soluble enzymes involved in particular meta-
bolic pathways, such as SULT, N-acetyl transferase (NAT),
certain glutathione transferases (GST), AO, and xanthine
oxidase (XO). For example, regioselective sulfation of the
phytoestrogens daidzein and genistein was investigated using
human liver cytosol and puriﬁed, recombinant human SULT
isoforms11. Additionally, cytosol assays are used to comple-
ment microsomal studies for assessing drug metabolism
pathways12.
S9, which contains both cytosol and microsomal enzymes,
is the sub-cellular fraction prepared by collecting the super-
natant after centrifugation of tissue homogenate at 9000 g.
One advantage of using S9 fractions over microsomes is its
ability to capture additional metabolism mediated by non-
CYP enzymes, such as sulfation and acetylation. Furthermore,
S9 allows cost savings and is easier to handle when compared
to primary hepatocyte incubations, which also provides a
complete collection of enzymes. To predict in vivo clearance,
the scale up factor (mg of S9 per gram of liver) from S9
incubations is scarcely available in the literature. It was
determined in one of the co-authors’ laboratory that there is
approximately 165 mg of S9 proteins per gram of rat liver13.
This value can be used to calculate intrinsic clearance across
all species (including humans), which in turn can be used to
calculate whole body clearance.
When working with sub-cellular fractions, it is important to
remember that the co-factors that mediate either the oxidative
metabolism (e.g., NADPH) or the conjugation reactions (e.g.,
uridine diphosphate glucuronic acid (UDPGA), 30-phosphoa-
denosine-50-phosphosulphate (PAPS) and S-adenosylmethio-
nine (SAM)) are lost in the process of isolation of those
fractions. Therefore, it is necessary to supplement the sub-
cellular fractions with these co-factors to initiate the various
enzymatic reactions. By including or excluding certain
co-factors, one can pinpoint the involvement of certain
metabolic pathways for a given compound. This application
was well demonstrated in the study of 17a-ethinylestradiol
metabolism by Li and colleagues14. One issue regarding the
use of S9 fractions is that the enzymes in S9 are not as
enriched as those in microsomes. A larger amount of S9
protein (usually 5-fold) is required to achieve a level of activity
seen in a comparable microsomal incubation. This condition
could result in higher protein binding of the test compound.
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for drug metabolism studies, with the advantages of being
inexpensive and easy to handle while containing the major
drug metabolism enzymes, e.g., CYPs and UGTs. Microsomal
assays are the default assays for metabolism and DDI studies
at the drug discovery stage. One application of microsomal
assay is to determine intrinsic clearance, a useful parameter for
facilitating the screening process for stable compounds and for
establishing an in vitro correlation between animals and
humans. Using microsomes from various tissues one can
assess extra-hepatic metabolism and further strengthen the
in vitro prediction of total body clearance by considering
multi-organ metabolism. Microsomal assays are also preferred
for determining DDI potential. Both reversible inhibition and
time-dependent inhibition studies provide information on the
possibility of the drug candidate being a perpetrator of DDI
for a co-administered drug. On the other hand, CYP reaction
phenotyping studies may answer whether the drug candidate
might be a victim if co-administered with a CYP inhibitor or
inducer. An additional feature of microsomes, that they
contain relatively concentrated CYP enzymes, makes them
useful for enzyme kinetic studies, which provide information
on such parameters as the Vmax and Km of a metabolic
pathway, the ki or IC50 for reversible inhibition, and the kinact
and KI for mechanism-based inhibition.2.1.3. Whole cell systems (hepatocytes, other cells
and cell lines)
Hepatocytes are the primary liver cells where drug metabolism
occurs. Hepatocytes cell membrane contains various uptake or
efﬂux transporters. Drugs could passively diffuse through the
hepatocyte membrane or be taken up by transporters, such as
OATP and sodium taurocholate cotransporting polypeptide
(NTCP), to enhance the intracellular concentration15. Once a
drug enters hepatocytes, the efﬂux transporters, such as P-gp,
BCRP and multi-drug resistance-associated proteins (MRP),
could pump the drug out, to reduce the intracellular drug
concentration. The primary cultures of hepatocytes carry
enzymes and co-factors at physiological concentrations and
provide a drug metabolism environment that closely mimics
the in vivo conditions. Freshly prepared hepatocytes are a
good model for drug metabolism and transporter studies;
however, their applications have limitations, including (1) they
are not readily available from humans and other higher
animals; (2) a preparation could only be used once, so it is
difﬁcult to repeat studies or compare studies between labora-
tories. These limitations can be overcome with cryopreserved
human hepatocytes, their utility in in vitro systems has
provided big advantages in drug discovery16,17. The pre-
characterized cryopreserved hepatocytes serve effectively as a
‘‘reagent’’ and allow researchers to perform experiments at
their own schedule and test drug candidates over a period of
time using the same lot(s) of hepatocytes. It also allows studies
to be directly compared between different laboratories. In
addition, the use of cryopreserved human hepatocytes permits
the choice of speciﬁc pre-characterized lots (donors) to meet
one’s research needs, such as studies in special populations of
smokers, alcohol users, or people with poor metabolism via
CYP2D6 or 2C19.
Hepatocytes are used in drug discovery studies as suspen-
sion or sandwich cultures. The suspension cultures are usedfor the study of metabolic stability or transporter-mediated
uptake of drug candidates. Studies using hepatocytes sus-
pended in plasma assist in the improvement of in vitro–in vivo
correlations in drug clearance and DDI predictions18–22. The
disadvantage of suspension culture is that the hepatocytes
have a limited viability and typically can be used for acute
dose-studies only, generally up to 4 h15,17. Hepatocytes cul-
tured on a collagen coated plastic surface extend the viable
period to 7–10 days. Despite decreases of CYP activities over
the culture period, the hepatocyte cultures still provide insight
to the effects of an increased exposure period on the test
compound and to secondary metabolite formation, as might
occur in in vivo situations. This assay format is also reported
to be superior for identiﬁcation of time-dependent inhibitors,
which would be missed in microsomal reactions with shorter
incubation time23,24. One major application of cultured hepa-
tocytes is for use in CYP induction studies, because enzyme
induction may involve gene transcription and translation, and
therefore may require time to take effect. In fact, primary
cultured human hepatocytes have become the ‘‘gold standard’’
for conducting CYP induction studies7,25,26. Cell lines, such as
Fa2N-4 and HepaRG, are also used for CYP induction
evaluations; however, reports suggest that some of the CYP
enzymes, such as CYP2B6, may be under represented in these
cell lines27,28.
Hepatocyte culturing for longer terms has become an
emerging area of research in the last decade. While there are
some progress, most of the successful examples are limited at
academic scale, such as the design of special formats or devices
for 2-D or 3-D culturing systems, with which specialty is
required to maintain and perform even a small scale study.
None of these systems is ready to be practically used for
commercial applications, such as industrial research for drug
screen and drug development.
Liu and colleagues29,30 have modiﬁed sandwich culture
conditions by adding a thick layer of MatrigelTM on top of
the hepatocytes, in order to study biliary excretion of com-
pounds. Under these conditions, healthy bile canaliculi
between hepatocytes were developed. When test compound
is incubated with hepatocytes, part of the test compound is
excreted into bile canaliculi and the rest remains in hepato-
cytes or medium. The tight junctions between the hepatocytes,
which prevent the compound from escaping the bile pockets,
can be opened, releasing the compound from bile pockets into
the media, by treatment of the hepatocytes with a calcium-free
medium (or EDTA-containing medium). The presence of the
canaliculi allows the quantiﬁcation of biliary excretion and
subsequent calculation of the biliary excretion index and
determination of clearance via biliary excretion, in a well
designed study. This application provides a major advantage
in that one could identify species similarities and ﬁnd a
preclinical species that can be used to predict clearance in
humans in vivo.2.2. In vitro transporter models
Transporters play important roles in drug disposition, drug–
drug interactions and drug toxicity. Approximate 400 human
transporters can be classiﬁed into ATP-binding cassette (ABC)
transporter and solute carrier (SLC) transporter families6. In
general, ABC transporters pump the substrates out of cells,
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porter substrates can be endogenous compounds or xenobio-
tics, including some drugs, drug candidates and their
metabolites. The key efﬂux transporters include P-gp, BCRP
and BSEP, whereas the important uptake transporters are
OATP1B1, OATP1B3, OAT1, OAT3, OCT1 and OCT26,7,31.
Determination of a drug candidate’s status as a transporter
substrate and/or inhibitor requires performance of a trans-
porter assay using one of the following in vitro experimental
models. Readers are referred to published reviews for detailed
information6,32,33.
2.2.1. Immortalized cell lines
Human colon cancer derived Caco-2 cell line is widely used as
a model of permeability and efﬂux transport (via P-gp and
BCRP). This is because Caco-2 cells undergo enterocytic
differentiation and become polarized in culture (usually for
21 days), resembling human intestinal epithelium in transpor-
ter expression and tight junction formation. The bi-directional
permeability assay using Caco-2 is the most popular method
for identiﬁcation of P-gp substrates and inhibitors in drug
discovery6,34 among the various in vitro models.
2.2.2. Transfected cell lines
Chinese hamster ovary (CHO) cells, Mardin-Darby canine
kidney (MDCK) cells, human embryonic kidney 293 cells
(HEK293) and pig kidney epithelial cells (LLC-PK1) are
commonly transfected to over-express a single transporter.
For certain efﬂux transporters transfected in MDCK cells,
co-expression of a corresponding uptake transporter is neces-
sary35,36. The transfection can be transient or permanent.
A permanent transfection cell line is usually favored over
transient transfection because the former produce more
reproducible data.
2.2.3. Hepatocytes
The liver plays a central role in drug metabolism and
disposition through its primary metabolic enzymes (both
Phase I and Phase II) and many transporters (including both
uptake transporters expressed on the sinusoidal membrane
and efﬂux transporters expressed on sinusoidal and canalicular
membranes). Therefore, freshly isolated hepatocytes are reg-
ularly used to determine hepatic metabolism and clearance
mediated by liver enzymes37, as well as to assess hepatic
uptake mediated by uptake transporters38,39. In experiments,
the uptake into hepatocytes is measured in suspension by a
centrifugation method, using oil-layered tubes to separate
hepatocytes from incubation medium. There have also been
reports that cryopreserved hepatocytes can be used for study-
ing hepatic uptake15. Isolated hepatocytes cannot be directly
used for efﬂux assay because the efﬂux transporters lose their
function during the isolation process; however, primary
cultures of hepatocytes can restore the function of efﬂux
transporters even though the uptake transporters demonstrate
decreased functionality in primary cultures.
2.2.4. Membrane vesicles
Membrane vesicles prepared from organs (such as liver,
kidney and intestine) that naturally express a high concentra-
tion of transporters or from transfected cell lines (such as
MDCK, HEK293 and LLC-PK1 cells) that over-express asingle transporter have been used to assess the transporter
mechanisms in liver, kidney and intestine33,40. A technical
beneﬁt of using membrane vesicles is that it allows separate
preparations of the blood side of cell membranes (liver-
sinusoidal, kidney and intestine-basolateral) and lumenal side
of cell membranes (liver-bile canalicular, the intestine and
kidney-brush-border) to ﬁt the research needs.
2.3. In situ and ex vivo models
2.3.1. In situ models (perfusion)
The organ perfusion model most closely mimics in vivo drug
absorption, transport, metabolism and excretion. Among
various organ perfusion models, the liver perfusion model is
the most studied. This model has the advantage over hepato-
cyte and other sub-cellular systems as it maintains the liver
structure and architecture, preserves all the transporters and
cell populations in addition to hepatocytes (e.g., the Kupffer
cells, which are important for regulation of proinﬂammatory
cytokines), and retains hepatocyte cell-to-cell interaction and
zonal differentiation. As an endpoint, the perfusate, bile and
liver tissue itself can all be analyzed for the parent compound
and its metabolites. This application provides information on
the extent of the hepatic ﬁrst-pass effect, effect of protein
binding, parent uptake from the perfusate, metabolism, parent
and metabolites elimination via canalicular transporters, as
well as the potential for toxicity from reactive metabolites.
The liver perfusion technique is also a useful tool for
toxicological and pharmacological studies41. The liver perfu-
sion technique has been standardized regarding the experi-
mental set up42,43 and the constituents of the perfusates
usually vary depending on the purpose of the study. Liver
perfusion can be performed in situ or in a setting where the
liver is isolated. The in situ perfusion model requires minimal
organ preparation, and therefore, the potential of organ
damage is minimized. However, isolated liver preparation
answers liver-speciﬁc mechanistic questions with no interfer-
ence from other organs, generally making this application a
more widely used model. Isolated liver perfusion systems are
commercially available (e.g., Harvard Apparatus, Holliston,
MA). When using the liver perfusion technique, the type of
perfusate used needs to be taken into account. Commonly
used perfusates contain varying amounts of matrix (including
albumin and/or red blood cell (RBC)), which may affect the
protein binding of the test compounds and their metabolism
and disposition. Heparinized whole blood from the same
species is perhaps the best perfusate. However, heparinized
whole blood is not always readily available and potential
issues such as the formation of clots must be taken into
consideration. As an alternative, bovine blood, bovine serum
albumin, and bovine or human erythrocytes have been used to
mimic in vivo conditions, because they provide hemoglobin as
the oxygen carrier and ideal protein binding conditions.
2.3.2. Ex vivo models for induction and toxicity studies
Ex vivo studies refer to ones where a drug is dosed to animals
and then the organ tissues are removed and processed (e.g.,
making liver into microsomes), and used for investigations of
the changes in expression levels of enzymes or transporters (or
any bio-markers) upon drug treatment. In general, mRNA
levels and/or activities are measured to represent the changes
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to the toxicology or pathology ﬁndings in the animal in-life
study. One of the most useful practices is to perform the
ex vivo study in parallel with toxicokinetics (TK) studies where
drugs are dosed at high levels (close to the maximum tolerable
dose). Pharmacokinetic information is then collected and used
to link with or explain the TK, PD or toxicity observations.
Usually, at the end of the sub-chronic or chronic dosing study,
organs are collected. Liver, the organ that is in most cases
exposed to high drug concentrations, is often studied for the
effect of drug on enzyme levels. The enzyme expression
changes could in turn explain changes in PK, or could be
linked to toxicity ﬁndings. Among various observations,
including changes of enzyme levels, PK, and toxicity, some
are directly linked to each other, whereas others may show
delayed responses. PK/PD modeling allows further prediction
through dissection of the response relationships. For example,
in a potential perspective and under a linear PK scenario, if a
decrease in drug exposure (AUC(0–24), day xoAUC(0-N), day 1)
is observed in an animal repeat-dosing study, it is often
considered to be due to an autoinduction by the drug of the
enzyme(s) that are responsible for its own metabolism.
By testing with CYP probe substrates in an ex vivo study,
the induction of CYPs by a drug can be determined. On the
other hand, if there is a drug accumulation (AUC(0–24), day
x4AUC (0-N), day 1), the drug could be a mechanism-based
inhibitor that inactivates the enzyme(s) responsible for its own
metabolism. One advantage of the ex vivo application is the
removal of the parent compound during the preparation of the
sub-cellular fractions, thus removing potential interference
from reversible inhibition by the parent compound.
2.4. In vivo models
The in vitro models discussed above have limited values, as they
reﬂect only one particular aspect of the whole picture. Whereas,
in vivo results are multi-factorial, provide the combined effect of
permeability, distribution, metabolism and excretion, and can
yield a measurable set of pharmacokinetic parameters and
toxicology endpoints. Regardless the thoroughness and comple-
teness of the in vitro work, animal studies are required to
measure drug exposures and to determine potential toxicities.
The current trend is to use rats as the ﬁrst animal species for
testing drug exposure because they are inexpensive and require
small amount of test compound. In vivo rat studies can help
identify ADME problems of a new chemical series, such as
whether low absorption or high clearance occurs, leading to
undesirable PK. Subsequently, in vitro models, such as Caco-2,
can be used to optimize absorption of compounds from the same
chemical series and microsomal stability assay can be applied to
select stable compounds. It should be reiterated that human-
based in vitro assays, relative to other assays, could provide
closer estimations of human clinical outcomes, especially for
properties that are known to have species differences (such as
CYP induction), but have good in vitro–in vivo correlations in
humans.
2.4.1. Pharmacokinetic studies
Understanding the pharmacokinetics of a compound in pre-
clinical species with various dose routes (oral, intravenous,
subcutaneous, transdermal, intraperitoneal, continuousinfusion, intratracheal, as well as access ports of the portal
vein) is an essential component for lead selection and optimi-
zation, and clinical candidate nomination and development.
Early in the discovery process, PK screening using various
dose regimens and administration routes in rodents or non-
rodents allows rapid eliminations of drug candidates, which
facilitate lead optimization and produce a candidate that is
more likely to succeed in preclinical testing and in the clinic.
Extensive PK studies are still necessary to evaluate the dose
proportionality, bioavailability or food effects in single or
multiple dose administration. These studies use compartmen-
tal and non-compartmental methods to determine multiple
parameters, including maximum concentration (Cmax), time of
maximum concentration (Tmax), AUC, volume distribution
(Vss), clearance (CL), terminal elimination half life (T1/2), and
bioavailability (F), thereby deﬁne the PK proﬁles of a
compound. Dispositional studies also provide data on mass
balance, biliary excretion and tissue distribution. Surgical
animal models for dosing and sampling can be used to provide
insight on biliary excretion from bile-duct cannulation and to
investigate ﬁrst-pass metabolism from vascular and portal vein
cannulation. The applications of animal models have been
extensively reviewed by Salyers44. Table 2 lists typical phar-
macokinetic studies in drug discovery, preclinical development
and safety, and clinical and bio-pharmacology studies.2.4.2. Preclinical ADME models
During the discovery stage, mass balance study and ADME
studies are conducted with non-radiolabeled compounds,
producing limited quantitation data for parent drug and
metabolites. In drug development, ADME studies are per-
formed with either 14C or 3H labeled material which provides
more detailed quantitative information on the circulating
metabolites, the extent of metabolism, and routes of excretion
of the drug and its metabolites. Zhang and Comezoglu45
provided a detailed review on ADME study design and
data presentation. Tissue distribution studies in pigmented
Long–Evans rats are usually conducted ﬁrst to provide
dosimetry for various tissues and organs, which supports
human ADME studies with radiolabeled compounds. Typi-
cally, these studies are limited to single dose by the intended
route of administration (PO, IV, etc.). The radioactivity levels
in various tissues at different time points are measured by
QWBA, a process where whole body animals sections are
exposed to a phosphorimaging screen and then scanned with a
phosphor imager. Based on body surface area and body
weight, tissue exposure to the radioactivity in the rat is
extrapolated to human tissues46. For most compounds,
administration of a 100-mCi radioactive dose typically exposes
the human subjects to an effective dose equivalent of o1
mSiv, well below the radiation limit set by the Nuclear
Regulatory Commission47. Tissue distribution studies have
additional applications; for example, the evaluation of
maternal–fetal transfers. These studies are required for the
IND and NDA ﬁlings and are typically conducted in the rat
strain used in the toxicological evaluation.
The preclinical species used in the mass balance studies
(referred as ADME studies in this section) are based on the
choice of species used in the long term safety evaluation of a
compound. These studies are designed to mimic the toxicology
studies as close as possible in factors such as dose and the
Table 2 Role of pharmacokinetic studies in drug discovery and development.
Stage PK study type Objective PK or TK parameter
Discovery Fast exposure and PK screening in
rat
To ﬁnd bioavailable compound AUC, Cmax
Single/multiple/IV dose in mouse,
rat, dog, or monkey
To compare PK parameters across species AUC, Cmax, Tmax, T1/2,
Vd, F
Allometric scaling from in vivo and
in vitro data to predict human dose
and PK
To predict human dose and PK parameters CL, AUC, Cmax, T1/2
and efﬁcacious dose
projection
Preclinical
develop/
safety
Formulation in animal species To determine best formulations for drug exposures AUC, Cmax
Single ascending dose TK in rat, dog,
or monkey
To determine NOAEL AUC, Cmax, exposure
multiples
Dose-range ﬁnding in rat, dog or
monkey
To determine safe doses Same as above
1-Month IND toxicology in rat To determine NOAEL Same as above
1-Month IND toxicology in dog or
monkey
To determine NOAEL Same as above
Long-term (0.25–1 year) toxicology
and 2-year carcinogenesis in mouse
and rat
To ensure safety in rat and mouse including
carcinogenicity
Same as above
Long-term (0.5–1 year) toxicology in
dog or monkey
To ensure safety in animal species Same as above
Clinical/
Bio-
Pharma
Single/multiple ascending dose To determine safety and maximum tolerability doses AUC, Cmax, Tmax, T1/2,
(Vd, F)
Radiolabeled ADME To determine parent and metabolite proﬁles Parent and metabolite
exposures
DDI with inhibitors (e.g.,
ketoconazole)
To test DDI potential AUC, Cmax, Tmax, T1/2,
(Vd, F)
DDI with an inducer (e.g., rifampin) To test DDI potential Same as above
DDI with other drugs (e.g., Co-meds,
pH modiﬁers)
To test DDI potential Same as above
Special populations (renal/hepatic
impair/age/gender, weight)
To test if dose needs be adjusted Same as above
Special studies (e.g., food effect,
bioavailabilityy)
To test variability Same as above
Late
clinical
Population kinetics To determine whether physiological conditions, such as
age, body weight, ethnical background, may have
inﬂuence in PK
Same as above
Donglu Zhang et al.556route of administration, and compound vehicle. The amount
of radioactive dose in animal species is determined by the PK
properties of the parent compound. The typical administered
radioactivity range of 1.5–100 mCi/kg should be sufﬁcient to
generate metabolic proﬁles in plasma at multiple time points
with adequate radioactive sensitivity. The duration of the
study is determined by the terminal half-life of the parent
compound in that species and is set toZ5-plasma half-lives.
For compounds with long half-lives, the duration of the study
can be based on the criteria where r1% of the total dose is
excreted in a given 24-h interval in both urine and feces.
Plasma, urine and fecal samples are collected during the
duration of the study to analyze for radioactivity and for
metabolite proﬁling. If needed, additional tissue samples are
collected to determine the concentration and accumulation of
drug and drug-related component in a particular tissue.
The ﬁrst set of information generated from the ADME
studies are the overall plasma proﬁles of total radioactivity
(TRA) versus time which is compared to plasma proﬁle of
parent versus time measured by a validated LC/MS/MS assay.
For those drugs where the parent is the major component at all
time points in plasma, the total radioactivity proﬁle usually
parallels the proﬁle of the parent. Metabolic proﬁles of plasmaconcentration over time generated by HPLC analysis, followed
by radioactivity and mass spectrometric detection, provides
exposure-related information for parent and metabolites in
humans and animal species. Mass balance and metabolic
proﬁles of urine and fecal samples generated in ADME studies
provide information about extent of metabolism and routes of
excretion for parent and metabolites. An example of adminis-
tration of [14C]-apixaban to healthy human volunteers shows
that the compound is excreted in both urine and feces48,49.
Based on urinary excretion and metabolites in feces, approxi-
mately 50% of the dose is absorbed when administered orally.
These types of information help to understand the quantitative
and qualitative differences in metabolism across species. If all
the metabolites that were generated in humans in vitro are also
observed in animals, it would suggest that the primary path-
ways of metabolism are similar across species. The combined
metabolic proﬁles in plasma, urine and feces contribute to our
knowledge of the complete distribution and disposition of the
drug. For drugs that tend to be in the 300–700 Da range and
are highly lipophilic in nature, metabolism and excretion
through the bile plays a major role in their disposition. For
these types of molecules, ADME studies conducted in bile-duct
cannulated (BDC) animals, where bile is collected during the
Preclinical experimental models of drug metabolism and disposition in drug discovery and development 557duration of the study, are exceptionally valuable, particularly if
conjugative pathways such as glucuronidation or sulfation are
involved in the metabolic clearance of the drug. Glucuronides
and sulfate conjugates can undergo hydrolysis in the large
intestine when excreted through the bile into the gastrointestinal
(GI) tract50,51. Therefore, in the absence of a bile proﬁle, the
role of conjugation in the overall metabolic clearance of the
drug would be missed. BDC studies are usually run for a
shorter duration than PK studies, 0–24 h in rat and 0–72 h in
dog or monkey. A reasonable mass balance can be achieved in
BDC animal studies for compounds that have short half-lives.
Where non-clinical data shows that most of the drug is excreted
in the feces through bile as conjugative metabolites, it is useful
to include a panel in the human ADME where bile can be
collected for a short duration. In one example, bile was
collected for a short duration (3–8 h) after dosing with [14C]-
muraglitazar. When the bile and fecal proﬁles were compared, it
became evident that the compound in the bile was excreted as
conjugates that were hydrolyzed during their passage through
the GI tract51,52. Data from the human ADME studies provide
information about the primary pathways of metabolism for the
compound. The metabolic pathways are determined through
the identiﬁcation of metabolites in plasma, urine and feces/bile,
which in turn lead to detailed reaction phenotyping studies to
identify the enzymes that generate the primary metabolites. The
use of metabolism data obtained from human ADME studies
in conjunction with reaction phenotyping provides critical
information for decision in aid of clinical DDI studies.2.5. Engineered mouse models
Engineered mouse models are increasingly used for the determi-
nation of the roles of CYP enzymes in drug metabolism and
toxicity. Mouse Cyp gene(s) have been replaced by human CYP
gene(s) in the mouse genome, to study the speciﬁc involvement of
the given mouse and/or human CYP(s) in various aspects of
ADME. Removing a cluster of Cyp gene allows the determina-
tion of combined functions of an entire Cyp gene subfamily. The
composite functions of all microsomal CYP enzymes can be
studied by removal or modiﬁcation of the NADPH-cytochrome
P450 reductase (Cpr) gene. All of these programmed genetic
changes in a cell-type-speciﬁc or tissue-selective fashion allows
speciﬁc contributions of an organ (e.g., the liver or the intestine)
to the metabolism and/or toxicity of a drug to be directly
determined in vivo. The potential of these engineered mouse
models for ADME applications is considerable. A number of
selected mouse models are introduced below with examples of
their applications in drug metabolism, pharmacokinetics, andTable 3 A list of selected Cyp-knockout and human CYP-transg
Cyp-knockout mouse Reference(s) Human
CYP-transgenic mou
Cyp1a1 Dalton et al.78 CYP1A1/2
Cyp1a2 Liang et al.79 CYP2A6
Cyp1b1 Buters et al.80 CYP2C18/2C19
Cyp2a5 Zhou et al.69 CYP2D6
Cyp2f2 Li et al.77 CYP2A13/2B6/2F1
Cyp2e1 Lee et al.70 CYP2E1
Cyp3a (gene cluster) van Herwaarden et al.55 CYP3A4toxicology studies brieﬂy described, emphasizing practical advice
on how to avoid potential confounding factors.2.5.1. Available mouse models
A partial list of available Cyp-knockout mouse models and
human CYP-transgenic mouse models are shown in Table 3.
The readers are referred to recent reviews for information on
additional mouse lines53. Notably, two knockout mouse lines,
e.g., Cyp1a1-null and Cyp1b1-null, can be intercrossed to
produce a double knockout mouse54, except in cases where the
two targeted genes are located close to each other (e.g.,
Cyp1a1 and Cyp1a2). In those two cases, a double knockout
model can be generated through genetic engineering in the
embryonic stem cells. An even more challenging case is when
multiple mouse Cyp genes occur in a gene cluster, such as the
mouse Cyp3a gene cluster. Other mouse Cyp gene clusters
include the Cyp2j cluster, the Cyp2d cluster, the Cyp2c cluster,
and the Cyp2a-b-f-g-s-t cluster. The presence of multiple
copies of structurally similar Cyp genes makes it difﬁcult
(and sometimes irrelevant) to identify the speciﬁc CYP iso-
form that is normally active in the metabolism of a given drug
in vivo. Instead, it makes sense to knockout all members of the
subfamily, and to determine the combined functions of the
CYP enzymes impacted by the genetic manipulation. Indeed,
this strategy has been successfully used in several cases, the
ﬁrst of which is the deletion of the Cyp3a gene cluster55.
The human CYP-transgenic mouse models are most often
prepared using a large gene fragment contained in a bacterial
artiﬁcial chromosome (BAC) clone, although cDNA-based
transgene constructs have also been used successfully (e.g., for
CYP2A656). The tendency for two CYP genes in a given CYP
gene subfamily to be located in close proximity in the genome,
and potentially sharing common regulatory sequences for gene
expression, has made it difﬁcult to produce single-gene trans-
genic models for some CYPs, such as CYP1A1/257, CYP2C18/
1958, and CYP2A13/2B6/2F159. As a result, mouse models
expressing two or more closely associated CYP genes were
produced. On the other hand, single-gene CYP-transgenic mice
have been intercrossed, in order to produce double transgenic
mouse models (e.g., CYP2D6/CYP3A4-transgenic60).
A Cyp-knockout mouse and a human CYP-transgenic
mouse can be crossbred, in order to produce so-called
‘‘CYP-humanized’’ mouse models, in which the human CYP
is expressed, but the orthologous mouse Cyp gene is inacti-
vated. For example, human CYP2E1-transgenic mouse was
intercrossed with Cyp2e1-null mouse to produce CYP2E1-
humanized mouse61. More recently, CYP3A4 transgenic
mouse with either hepatic or intestinal CYP3A4 expressionenic mouse models.
se
Reference(s)
Jiang et al.57
Zhang et al.56
Lo¨fgren et al.58
Corchero et al.73
Wei et al.59
Cheung et al.61
Cheung et al.76, Granvil et al.82, van Herwaarden et al.55,81
Donglu Zhang et al.558was intercrossed with Cyp3a-null mouse, yielding CYP3A4-
humanized mouse models55.
A unique group of knockout mouse models, in which the
Cpr gene is targeted, is worth noting. CPR is the obligate
redox partner for microsomal P450 enzymes; therefore, the
deletion of the Cpr gene causes the inactivation of all
microsomal P450 enzymes in targeted cells. Several mouse
models, in which the Cpr gene has been deleted in a tissue-
speciﬁc fashion, are available, such as liver-speciﬁc Cpr-null
mice62,63 or intestinal epithelium-speciﬁc Cpr-null mice64. A
transgenic mouse (known as ‘‘Cpr-low’’ mouse), in which Cpr
expression was globally down-regulated65, as well as an extra-
hepatic Cpr-low mouse model, in which Cpr expression is
normal in hepatocytes, but low elsewhere66, are also available.2.5.2. Utility of engineered mouse models
Drug metabolism can play an essential role in the extent of
tissue exposure to either the parent compound or, in the case
of a prodrug, the active metabolite(s). Numerous mechanistic
questions related to drug metabolism or toxicity can be
answered through the use of a proper engineered mouse
model, thus facilitating preclinical drug safety and pharmaco-
kinetics studies. Some examples of the types of questions that
can be addressed are shown below.(1) Is in vivo metabolism mediated mainly by P450 or by
other drug-metabolism enzymes? Examples of this type
of application include the use of the Cpr-low mouse for
demonstration of the role of P450 enzymes in the
clearance of nifedipine67, and the use of the liver-Cpr-
null mouse for demonstration of the lack of a signiﬁcant
contribution by P450 enzymes to systemic acetamino-
phen clearance68.(2) Which P450 enzyme(s) are critical for in vivo metabo-
lism? For example, the Cyp2a5-null mouse was used for
demonstration of the role of CYP2A5 in the in vivo
clearance of nicotine; the deletion of the Cyp2a5 gene led
to substantial increases in the exposure of nicotine69.(3) Is a given drug-metabolism enzyme responsible for
bioactivation and consequent toxicity? For example,
the critical role of CYP2E1 in acetaminophen-induced
hepatotoxicity70, and the lack of an essential role by
CYP1A2 in acetaminophen-induced olfactory toxicity71,
was demonstrated through the use of the respective Cyp-
knockout mouse models.(4) Does the small intestine play a major role in ﬁrst-pass
clearance of a given oral drug? For example, the IE-Cpr-
null mouse was used to show that intestinal P450
enzymes play a major role in the ﬁrst-pass clearance of
oral nifedipine64. The small intestinal CYP3A4-huma-
nized mouse model (SI-selective expression of CYP3A4
and whole body knockout of all Cyp3a genes) was used
to demonstrate the capability of SI CYP3A4 to reduce
the bioavailability of oral docetaxel55.(5) For compounds metabolized through multiple pathways,
which pathway leads to active (or reactive) metabolites
in vivo? For example, CPR/P450 of the cardiomyocyte
was found not to be essential for the cardiotoxicity of
doxorubicin, an anticancer drug, which can be metabo-
lized by multiple enzymes, including CPR and carbonyl
reductase, in a study that used a cardiomyocyte-speciﬁc
Cpr-null mouse72. On the other hand, hepatic CPR/P450enzymes were found to be essential for the hepatotoxicity
and renal toxicity of acetaminophen, which can be
metabolized by both phase I and phase II enzymes68.(6) What is the capability of a human P450 enzyme to
produce a given metabolite (including reactive intermedi-
ates) in vivo? For examples, the in vivo capabilities of
human CYP2A6 to generate 7-hydroxycoumarin from
coumarin56; of human CYP2D6 to produce 4-
hydroxydebrisoquine from debrisoquine73; and of human
CYP3A4 to produce various metabolites from doce-
taxel55, or to produce 10-hydroxymidazolam from mid-
azolam73, have been assessed using the respective CYP-
transgenic mouse models.(7) What is the impact of genetic polymorphisms in drug-
metabolism genes on drug clearance? Few transgenic
mouse models that express allelic variants of P450 genes
have been reported; however, a wild-type mouse model,
as compared to a human CYP-transgenic mouse model,
or a Cyp-knockout mouse model, as compared to a
CYP-humanized mouse model, can represent a mouse
model containing a null allele for the human P450 gene.
Furthermore, hemizygotes and homozygotes human
CYP-transgenic mouse models can be compared for
studying effects of losing one CYP allele on systemic
drug clearance.The extent to which each of the available mouse models has
been characterized varies considerably; but it is essential that
the user is aware of the properties and limitations of each
model. It is beyond the scope of this review to provide detailed
information about each of the available mouse models. It
should also be noted that engineered mouse models are also
available for a number of drug transporters (e.g., see Kita-
mura et al.74, for a recent review) and phase II biotransforma-
tion enzyme, such as UGT175.3. Summary
Drug discovery and development remain as a complicated
models-based experimental scientiﬁc exploration. These mod-
els provide a variety of data, resulting from studies on in vitro
systems, in vivo animal species, and healthy human subjects,
for predicting the behavior of a drug in patients. These data
either address a particular aspect of drug metabolism, such as
permeability and transporter properties, as derived from
Caco-2 models or reveal entire distributional and dispositional
properties of a drug, as obtained from a human ADME study
using 14C-labeled compounds. Fig. 3 contains a summary of
the mechanistic input and relevance of major experimental
models that are used in drug discovery and development. The
selection of an appropriate model, followed by the application
of the speciﬁc model(s) with a speciﬁc strategy and correct
data interpretation, is critical. This review has described some
of the more prevalent experimental models used in drug
metabolism and disposition. Most modern drugs are discov-
ered and developed with the timely applications of the
appropriate experimental models. Certainly, there will be
additional, newer, and better modiﬁed models developed in
the future to support an efﬁcient drug discovery and develop-
ment process.
Figure 3 The relevance and signiﬁcance of ADME models in
drug metabolism and disposition for human clinical prediction.
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